| 2026-08-12 | 8-K | Form 8-K |
| 2026-08-10 | Deck | SANRECO Phase 2 Topline Results Webcast |
| 2026-08-10 | Press release | Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results |
| 2026-08-10 | 8-K | Form 8-K |
| 2026-08-10 | 8-K | Form 8-K |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-10 | Transcript | Earnings call transcript |
| 2026-07-16 | 8-K | Form 8-K/A |
| 2026-06-23 | 8-K | Form 8-K |
| 2026-06-16 | 8-K | Form 8-K |
| 2026-06-11 | Press release | Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Pr |
| 2026-06-11 | 8-K | Form 8-K |
| 2026-05-27 | Press release | Silence Therapeutics to Participate in Jefferies Global Healthcare Conference |
| 2026-05-18 | 8-K | Form 8-K |
| 2026-05-12 | Press release | Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference |
| 2026-05-11 | Document | Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice |
| 2026-05-07 | Press release | Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Annual report | UK Annual Report · 2025 |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-03-05 | Press release | Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Res |
| 2026-03-05 | 8-K | Form 8-K |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2025-12-22 | 8-K | Form 8-K |
| 2025-12-22 | 8-K | Form 8-K/A |
| 2025-12-15 | 8-K | Form 8-K |
| 2025-11-06 | 8-K | Form 8-K |
| 2025-11-06 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-23 | 8-K | Form 8-K |
| 2025-08-14 | 8-K | Form 8-K |
| 2025-08-07 | 8-K | Form 8-K |
| 2025-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-06-27 | 8-K | Form 8-K |
| 2025-06-12 | Deck | SANRECO, an On-going Phase 1/2 Study Evaluating Divesiran, a Novel GalNAc-conjugated SiRNA, in Patients with Polycythemi |
| 2025-05-16 | Proxy | Definitive proxy statement |
| 2025-05-08 | 8-K | Form 8-K |
| 2025-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-05-06 | 8-K | Form 8-K |
| 2025-04-30 | 10-K | Annual report on Form 10-K/A, FY24 |